Retatrutide
Money Back Guarantee
Easy Returns
Secure Ordering
2-Day Shipping
Third Party Tested
Batch & Lot TrackingLab results
Retatrutide 20 mgCurrent99.73%
- Report ID
- MSF-202605-9882
- Sample
- Retatrutide (CAS 2381089-83-2)
- Identity
- Confirmed by LC-MS / HRMS
- Net content
- 20.33 mg
- Endotoxin
- Pass (both replicates)
- Received
- May 6, 2026
These compounds are NOT intended for human consumption, clinical use, or veterinary applications. We are not affiliated with any pharmaceutical companies or their commercial medications. By placing an order, you certify these materials will be used exclusively for in vitro testing and laboratory experimentation only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.
About Retatrutide
Retatrutide is a GGG tri-agonist peptide developed for the simultaneous activation of the GLP-1, GIP, and glucagon receptors. Researchers evaluating Retatrutide in the laboratory can study a signaling profile distinct from single or dual agonists. Senna provides high-purity research-use-only material synthesized for in-vitro and animal-model research, with independent third-party verification.
Specifications
- Product Format
- Retatrutide lyophilized powder in a 3 mL vial
- Application
- Triple-agonist metabolic pathway research
- Appearance
- Solid white powder in a 3 mL glass ampule
- Chemical Formula
- C223H343F3N46O70
- PubChem SID
- 474492235
- CAS Number
- 2381089-83-2
- Molecular Weight
- Approximately 4845.444 g/mol
- Synonyms
- Retatrutide, GLP3, GGG Peptide, Triple G Peptide, LY3437943, GGG Tri-agonist, Reta
- Storage
- Store sealed at or below 25 C, protected from heat, light, and moisture
